Literature DB >> 22094060

Hydrophobic statins induce autophagy and cell death in human rhabdomyosarcoma cells by depleting geranylgeranyl diphosphate.

Makoto Araki1, Masatomo Maeda, Kiyoto Motojima.   

Abstract

Statins are the most common type of medicine used to treat hypercholesterolemia; however, they are associated with a low incidence of myotoxicity such as myopathy and rhabdomyolysis. The mechanisms for the adverse effects remain to be fully elucidated for safer chronic use and drug development. The results of our earlier work suggested that hydrophobic statins induce autophagy in cultured human rhabdomyosarcoma A204 cells. In this study, we first confirmed the statin-induced autophagy by assessing other criteria, including induced expression of the autophagy-related genes, enhanced protein degradation of autophagy marker protein p62 and electron microscopic observation of induced formation of autophagosome. We next demonstrated that the extent of inhibition of HMG-CoA reductase in the cell is parallel with the ability of a statin to induce autophagy. Thus, the primary activity of statins causes autophagy in A204 cells. Considering the mechanism for the induction, we showed that statins induce autophagy by depleting cellular levels of geranylgeranyl diphosphate (GGPP) mostly through an unknown pathway that does not involve two major small G proteins, Rheb and Ras. Finally, we demonstrated that the ability of statins to induce autophagy parallels their toxicity to A204 cells and that both can be suppressed by GGPP.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22094060     DOI: 10.1016/j.ejphar.2011.10.044

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  24 in total

1.  Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials.

Authors:  Katrijn Bogman; Jochen Brumm; Carsten Hofmann; Mylène Giraudon; Markus Niggli; Carolina Sturm-Pellanda; Annette Sauter; Stefan Sturm; Bernhard Mangold; Christophe Schmitt
Journal:  Clin Pharmacokinet       Date:  2019-09       Impact factor: 6.447

2.  Mitophagy protects against statin-mediated skeletal muscle toxicity.

Authors:  Mridula Ramesh; Juliane C Campos; Pamela Lee; Yang Song; Genaro Hernandez; Jon Sin; Kyle C Tucker; Hannaneh Saadaeijahromi; Michael Gurney; Julio C B Ferreira; Allen M Andres
Journal:  FASEB J       Date:  2019-08-23       Impact factor: 5.191

Review 3.  Statin treatment, new-onset diabetes, and other adverse effects: a systematic review.

Authors:  Casper N Bang; Peter M Okin
Journal:  Curr Cardiol Rep       Date:  2014-03       Impact factor: 2.931

4.  The UPRmt Protects Caenorhabditis elegans from Mitochondrial Dysfunction by Upregulating Specific Enzymes of the Mevalonate Pathway.

Authors:  Olga Oks; Shany Lewin; Irina Langier Goncalves; Amir Sapir
Journal:  Genetics       Date:  2018-03-29       Impact factor: 4.562

5.  Mitophagy is required for acute cardioprotection by simvastatin.

Authors:  Allen M Andres; Genaro Hernandez; Pamela Lee; Chengqun Huang; Eric P Ratliff; Jon Sin; Christine A Thornton; Marichris V Damasco; Roberta A Gottlieb
Journal:  Antioxid Redox Signal       Date:  2013-09-20       Impact factor: 8.401

6.  Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction.

Authors:  Hye Jin Wang; Jae Yeo Park; Obin Kwon; Eun Yeong Choe; Chul Hoon Kim; Kyu Yeon Hur; Myung-Shik Lee; Mijin Yun; Bong Soo Cha; Young-Bum Kim; Hyangkyu Lee; Eun Seok Kang
Journal:  Autophagy       Date:  2015-11-02       Impact factor: 16.016

7.  Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism.

Authors:  Jordan M Thompson; Alejandro Alvarez; Monika K Singha; Matthew W Pavesic; Quy H Nguyen; Luke J Nelson; David A Fruman; Olga V Razorenova
Journal:  Mol Cancer Ther       Date:  2018-05-02       Impact factor: 6.261

8.  Development of AD-Like Pathology in Skeletal Muscle.

Authors:  X Chen; N M Miller; Z Afghah; J D Geiger
Journal:  J Parkinsons Dis Alzheimers Dis       Date:  2019-04-02

9.  Treatment of human muscle cells with popular dietary supplements increase mitochondrial function and metabolic rate.

Authors:  Roger A Vaughan; Randi Garcia-Smith; Miguel A Barberena; Marco Bisoffi; Kristina Trujillo; Carole A Conn
Journal:  Nutr Metab (Lond)       Date:  2012-11-13       Impact factor: 4.169

10.  Selected statins produce rapid spinal motor neuron loss in vitro.

Authors:  Beth B Murinson; Norman J Haughey; Nicholas J Maragakis
Journal:  BMC Musculoskelet Disord       Date:  2012-06-15       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.